Diligence memo · auto-generated · as of July 2, 2026
Processa Pharmaceuticals, Inc.
Processa Pharmaceuticals, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Processa Pharmaceuticals, Inc. operates in Pharmaceuticals, based in HANOVER.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Processa Pharmaceuticals, Inc. has raised $29M in disclosed capital across 11 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $10M on 2021-02-16.
Most recent recorded round closed around 2021-02-16.
Valuation (modeled)modeled
Provath models Processa Pharmaceuticals, Inc. at approximately $239M (range $12M–$1.1B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.57× the median modeled value of Series A Pharmaceuticals companies in 2019–2021 (76 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 10 months.
Last raise 5.4 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 4.1× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 73% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 71% of those peers.
Closest niche peers: Xynomic Pharmaceuticals Holdings, Inc., Honest Globe Inc., Athenen Therapeutics, Inc., Zomedica Pharmaceuticals Corp., CerSci Therapeutics Inc..
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.